Johnson & Johnson reports 73% PSA response rate with investigational pasritamig-based immunotherapy combination in advanced prostate cancer
Johnson & Johnson reported first-in-human Phase 1 results showing a 73% PSA response rate (11 of 15 patients achieving at least 50% reductions) for the investigational combination of pasritamig and JNJ-9401 in metastatic castration-resistant prostate cancer. The dual-antigen bispecific regimen targets KLK2 and PSMA with complementary T-cell signals; 47% of patients achieved at least 90% PSA reductions, with no Grade 3 or higher treatment-related adverse events and only mild CRS in 20% of patients.
Key figures
- Drug Name
- pasritamig + JNJ-9401
- Phase Of Trial
- Phase 1 (advancing to Phase 3 KLK2-comPAS)
- Crs rate
- 20% (all Grade 1)
- Dosing schedule
- every six weeks
- Patients enrolled
- 144
- Psa50 response rate
- 73% (11 of 15 patients)
- Psa90 response rate
- 47% (7 of 15 patients)
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.